New England Journal of Medicine · 1969 · 60 citations · 10 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsAsthma ManagementAsthma PharmacotherapyBronchodilator TherapyInhalation Dosage FormsRespiratory MedicineRespiratory PharmacologyAsthma Bronchodilator TherapyBeta-adrenergic AgentsBeta-adrenergic Receptor PharmacodynamicsBeta2-adrenergic Agonist TherapyBronchodilator EfficacyDouble-blind TrialsHeart RatePharmacodynamics Of Inhaled Drugs
In a double-blind crossover trial in patients with asthma, similar initial bronchodilator activity was achieved with inhalations of salbutamol (100 μg), a new beta-adrenergic receptor-stimulating drug, and isoproterenol (500 μg), but the duration of action was longer with salbutamol. Heart rate did not increase with salbutamol but showed a small rise with isoproterenol. Normal subjects were given five times this dose of each drug. Salbutamol produced a small mean increase in heart rate (4 beats a minute) and no palpitation, whereas isoproterenol produced a large mean increase in heart rate (33 beats a minute) and pronounced palpitation. For comparable bronchodilator activity salbutamol appears to cause much less cardiovascular beta-receptor stimulation than isoproterenol, and it may prove to be more useful in the treatment of asthma.
10
Salbutamol: a new, selective β‐adrenoceptive receptor stimulant
VALERIE A. CULLUM, J B Farmer, David Jack et al. · British Journal of Pharmacology · 1969 · 297 citations · Full text
R T Brittain, J B Farmer, David Jack et al. · Nature · 1968 · 136 citations
ISOPRENALINE RESISTANCE AND THE USE OF PRESSURISED AEROSOLS IN ASTHMA
James W. Paterson, M. E. Conolly, D. S. Davies et al. · The Lancet · 1968 · 117 citations